Table 3.
Factors related to the performance of prostate-specific antigen testing in a cohort of French men aged 50 to 74 years (mixed-effects multivariate logistic regression with general practitioner as a random effect).
| Characteristics | Proportion of patients screened using PSAa,b (%) | Crude odds ratio (95% CI)c | P valued | Adjusted odds ratio (95% CI)e | P valuef | ||
| Age in years | N/Ag | 1.09 (1.09-1.10) | <.001 | 1.07 (1.07-1.07) | <.001 | ||
| Low socioeconomic statush | 23.55 | 0.43 (0.39-0.48) | <.001 | 0.61 (0.55-0.68) | <.001 | ||
| Frail individual | |||||||
|
|
Chronic disease status | 46.28 | 1.42 (1.37-1.46) | <.001 | 0.79 (0.76-0.83) | <.001 | |
|
|
Repeated ambulance transportation | 24.55 | 0.42 (0.33-0.53) | <.001 | 0.29 (0.23-0.38) | <.001 | |
|
|
Chronic treatment with ≥5 drugs | 50.46 | 1.66 (1.59-1.73) | <.001 | 0.89 (0.83-0.96) | .002 | |
| Cancer disease (treated with anticancer drug) | 37.48 | 0.83 (0.70-1.01) | .06 | 0.67 (0.55-0.83) | <.001 | ||
| Cardiovascular disease | |||||||
|
|
Number of cardiovascular drugs |
|
|
|
|
|
|
|
|
|
0 | 31.11 | Reference | N/A | Reference | N/A |
|
|
|
1-2 | 51.31 | 2.66 (2.56-2.75) | <.001 | 2.23 (2.15-2.32) | <.001 |
|
|
|
3-4 | 53.69 | 2.98 (2.86-3.12) | <.001 | 2.61 (2.46-2.77) | <.001 |
|
|
|
5 or more | 49.59 | 2.46 (2.34-2.59) | <.001 | 2.64 (2.40-2.91) | <.001 |
|
|
Treated with insulin | 38.51 | 0.87 (0.79-0.96) | .005 | 0.55 (0.49-0.61) | <.001 | |
|
|
Treated with antiaggregant | 51.17 | 1.80 (1.73-1.86) | <.001 | 0.91 (0.86-0.96) | .001 | |
| Dementia (treated with anticholinesterase therapy) | 53.17 | 1.46 (0.99-2.17) | .06 | N/A | N/A | ||
| Psychiatric disorder (treated with antipsychotic therapy) | 35.73 | 0.79 (0.72-0.86) | <.001 | N/A | N/A | ||
| Other variables indicative of comorbidities | N/A | N/A | |||||
|
|
Oxygen at home | 41.79 | 1.02 (0.95-1.10) | .51 |
|
|
|
|
|
>8 urea/creatinine tests during the study period | 40.50 | 0.98 (0.85-1.12) | .72 |
|
|
|
|
|
>4 alpha-fetoprotein tests during the study period | 41.71 | 1.02 (0.75-1.38) | .92 |
|
|
|
aProstate-specific antigen.
b n=98,107.
cGeneral practitioner as a random effect; bivariate analysis.
dP value for crude odds ratio.
eGeneral practitioner as a random effect; multivariate analysis; adjusted on the variable “treatment for benign prostate hyperplasia.”
fP value for adjusted odds ratio.
gN/A: not applicable.
hDefined as an annual income less than 8593 € (US $9992) for an individual or less than 12889 € (US $14,925) for a couple.